Product Datasheet  
RelB(Ab-573) Antibody  
Catalog Number: 21247  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species：  
  • Rabbit
  • Amount：  
  • 100μgμg
  • Swiss-Prot No.：  
  • Swiss-Prot: Q01201
    NCBI Protein: NP_006500.2
  • Form of Antibody：  
  • Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
  • Storage：  
  • Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.
  • Immunogen：  
  • Peptide sequence around aa. 550~554 (L-L-S-P-G) derived from Human RelB.
  • reactivity：  
  • Hu Ms Rt
  • appl_detail：  
  • Predicted MW: 70kd
    Western blotting: 1:500~1:1000
  • other_names：  
  • I-Rel
  • Purification：  
  • Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
  • Specificity：  
  • The antibody detects endogenous level of total RelB protein.
  • Applications：  
  • WB
  • Background：  
  • NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.

    Baeuerle, P.A. and Henkel, T. (1994) Annu Rev Immunol 12, 141-79.
    Baeuerle, P.A. and Baltimore, D. (1996) Cell 87, 13-20.
    Haskill, S. et al. (1991) Cell 65, 1281-9.
    Thompson, J.E. et al. (1995) Cell 80, 573-82.




 
© Signalway Biotechnology All Rights Reserved.